Tag:
PRX302
Latest Headlines
Latest Headlines
Protox gets $3M upfront in $75M deal with Kissei
Canada's Protox Therapeutics has landed a $75 million development and commercialization agreement with Japan-based Kissei Pharmaceutical. The $75 million deal covers PRX302, Protox's PSA-activated
